Members Only Content

Subscribe to get full access

Free Preview

Pre-commercial drug developers don't have traditional fundamentals to analyze, but investors can estimate the likelihood of clinical development. 7investing Lead Advisors Simon Erickson checks in with Maxx Chatsko on his new quest to build accurate, risk-adjusted net present value (rNPV) models for drug developers.

related news & insights

  • February 1, 2025||4.9 min||||

    X’s Favorite Small-Cap Growth Stocks

    We did something special this month. In addition to sharing our 7investing Community's favorite new ideas, we also asked an [...]

  • January 30, 2025||10 min||||

    “Staying Focused”: Here’s Why STAAR Surgical Has 41% Upside

    See my previous Discounted Cash Flows for Coupang , Rocket Lab , Tesla, and The Trade Desk. Some investors describe [...]

  • January 10, 2025||0 min||||

    Coupang Deep Dive: January 2025

    CPNG Recommendation Jan 2025